S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Generative AI boosts UiPath; analysts see triple-digit EPS growth
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Generative AI boosts UiPath; analysts see triple-digit EPS growth
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Generative AI boosts UiPath; analysts see triple-digit EPS growth
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Generative AI boosts UiPath; analysts see triple-digit EPS growth
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Neovasc Stock Price, News & Analysis (NASDAQ:NVCN)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$30.03
$30.03
50-Day Range
$29.03
$30.03
52-Week Range
$4.59
$30.07
Volume
1 shs
Average Volume
56,993 shs
Market Capitalization
$82.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVCN stock logo

About Neovasc Stock (NASDAQ:NVCN)

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.


NVCN Stock News Headlines

Closing Bell: Neovasc Inc down on Tuesday (NVCN)
Closing Bell: Neovasc Inc up on Monday (NVCN)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Neovasc Announces German Reimbursement Renewal
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Neovasc Announces Progress on COSIRA-II Clinical Trial
Neovasc Third Quarter 2022 Earnings: Misses Expectations
Form 6-K NEOVASC INC For: Sep 20 - StreetInsider.com
Neovasc Announces Key Events at TCT 2022 - GlobeNewswire
See More Headlines
Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
12/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCN
Employees
49
Year Founded
N/A

Profitability

Net Income
$-41,200,000.00
Net Margins
-1,082.92%
Pretax Margin
-1,082.26%

Debt

Sales & Book Value

Annual Sales
$3.81 million
Book Value
$5.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$82.28 million
Optionable
Not Optionable
Beta
1.70
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Fredericus Antonius Colen
    President, Chief Executive Officer & Director
  • Bill Little
    Chief Operating Officer
  • Christopher Clark
    Chief Financial Officer & Secretary
  • Sarah Gallagher
    Vice President-Clinical Affairs
  • Shmuel Banai
    Medical Director














NVCN Stock Analysis - Frequently Asked Questions

Should I buy or sell Neovasc stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVCN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCN, but not buy additional shares or sell existing shares.
View NVCN analyst ratings
or view top-rated stocks.

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) released its earnings results on Tuesday, November, 9th. The medical equipment provider reported ($2.75) earnings per share for the quarter, missing analysts' consensus estimates of ($2.25) by $0.50. The medical equipment provider earned $0.70 million during the quarter, compared to analyst estimates of $1.20 million. Neovasc had a negative net margin of 1,082.92% and a negative trailing twelve-month return on equity of 127.25%. During the same quarter in the prior year, the firm earned ($12.75) earnings per share.

When did Neovasc's stock split?

Shares of Neovasc reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Neovasc own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Palatin Technologies (PTN), Amarin (AMRN).

This page (NASDAQ:NVCN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -